Radiation Oncology/Therapy: Page 110

Second cancer risk in childhood cancer survivors increased lifelong
By Reuters Health
NEW YORK (Reuters Health), Jun 9 - Survivors of childhood cancer face a lifelong increased risk of second primary cancers, according to a report in the June 2 issue of the Journal of the National Cancer Institute.
June 8, 2009
Reuterslogo
Eckert & Ziegler seeks to halt takeover
By AuntMinnieEurope.com staff writers
Radiotherapy and radioisotope developer Eckert & Ziegler Isotope Products plans to file an appeal this week to block a decision by the Belgian securities regulator (CBFA) for the company to begin a mandatory public takeover bid on International Brachytherapy at 3.47 euros ($4.85 U.S.) per share.
May 31, 2009
Stereotactic body radiation slows lung cancer
By Reuters Health
NEW YORK (Reuters Health), May 22 - Stereotactic body radiation therapy appears to be highly effective for treating certain patients with non-small cell lung cancer, providing a three-year local tumor control rate of 90% or higher with minor toxicity, Scandinavian researchers report in a May 4 online edition of the Journal of Clinical Oncology.
May 21, 2009
Reuterslogo
Intraop scores Belgian order
By AuntMinnieEurope.com staff writers
Intraoperative radiation therapy firm Intraop Medical has received an order for its Mobetron from the Institut Jules Bordet in Brussels.
May 19, 2009
Audio and visual aids decrease radiation therapy treatment times
By Cynthia E. Keen
Use of respiratory-gating techniques during free breathing reduces healthy tissue exposure to radiation, but has the drawback of longer radiation therapy delivery times. Belgian researchers may have found a solution in an inexpensive, low-tech technique: At their center, visually guided voluntary breath-hold along with audio assistance reduced treatment time duration so that it's comparable to conventional treatment times.
May 18, 2009
Elekta, Nucletron ink Mosaiq deal
By AuntMinnieEurope.com staff writers
Radiation oncology firm Nucletron will market and license Mosaiq software from Swedish oncology firm Elekta.
May 18, 2009
IBA posts Q1 numbers, inks proton deal
By AuntMinnieEurope.com staff writers
The effects of a lackluster worldwide economy resulted in a mediocre financial report from Ion Beam Applications (IBA) in the first quarter.
May 10, 2009
New technology spurs investment in brachytherapy
By Marvin Burns
The U.S. market for brachytherapy products should exceed $1 billion in the next five years, driven by the introduction of new products that allow accelerated treatment for cancer patients after surgery. The worldwide market could grow even more rapidly, according to this analysis from market research firm Bio-Tech Systems.
April 22, 2009
Homeopathy appears compatible with cancer therapy
By Reuters Health
NEW YORK (Reuters Health), Apr 15 - There is limited evidence that homeopathic remedies ease the side effects of cancer treatments, but they at least seem to cause no serious adverse effects or drug interactions, according to a report published Tuesday.
April 14, 2009
Reuterslogo
Drug boost plus radiotherapy promising in glioblastoma
By Reuters Health
NEW YORK (Reuters Health), Apr 13 - Intensive treatment with a combination of lomustine, temozolomide, and radiotherapy can achieve long-term survival in patients newly diagnosed with glioblastoma, German and Swiss researchers report in the March 10 issue of the Journal of Clinical Oncology.
April 12, 2009
Reuterslogo
Single-entry APBI offers flexibility in treating breast cancer
By Cynthia E. Keen
Until recently, accelerated partial-breast irradiation (APBI) was not an option for most women with small breasts or a tumor located close to the chest wall and lung or the surface of the skin. The introduction of multicatheter single-entry brachytherapy devices, however, is beginning to change the situation.
April 2, 2009
High-dose brachytherapy shortens cancer treatment
By AuntMinnieEurope.com staff writers
Perioperative high-dose-rate brachytherapy, when combined with intermediate-dose external-beam radiation therapy (EBRT), can be effective as an alternative to full-dose EBRT in patients with unirradiated squamous cell cancer of the oral cavity and oropharynx.
March 29, 2009
Previous Page
Page 110 of 127
Next Page